Trial Profile
A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Metformin (Primary) ; Olaparib (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions
- Acronyms ENDOLA
- 13 Apr 2022 Results assessing the safety and efficacy of the triplet olaparib (PARP 1-3 inhibitor) + metronomic cyclophosphamide + metformin in patients with advanced endometrial carcinoma, presented at the 113th Annual Meeting of the American Association for Cancer Research.
- 06 Dec 2021 Status changed from active, no longer recruiting to completed.
- 30 Jan 2021 This trial has been completed in France, according to European Clinical Trials Database record.